Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope
Author(s): Demilade Adedinsewo Added: 1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction … View more

Demographic

Heart Failure
Updates in HCM Management
Author(s): Elena Arbelo , Juan-Pablo Kaski Start date: Aug 27, 2023
Live from ESC 2023 in Amsterdam, this broadcast will bring together the chairpersons of the latest ESC Guidelines on Cardiomyopathy, released on Sunday 27 August 2023. Prof Elena Arbelo (Hospital Clinic, Barcelona, ES) andProf Juan Pablo Kaski (University College London, UK) will provide definitive commentary on the guideline updates – including what's new in hypertrophic cardiomyopathy (HCM),… View more

Guidelines & Statements

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 6 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 1 month ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 1 year ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 1 year ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 1 month ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 2 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
Women As One CLIMB® 2024 Skills Training Program
Author(s): Victoria Delgado , Laura Sanchis , Julia Grapsa , et al Added: 4 months ago
About the CLIMB® Skills Training ProgramNow in its fifth year,the CLIMB program hasprovided free,advanced clinical skills training to over 390women physicians from 99 countries.This online program helps address the underrepresentation ofwomenin advanced procedural cardiology subspecialties.Physicians worldwide will now have on-demand access to didactic presentations delivered by leading faculty… View more

Demographic

Electrophysiology & Arrhythmia
ACC 24 Late-Breaker Discussion: The ARISE-HF Trial
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,… View more

Heart Failure

Prevention & Chronic Conditions